Pedro Jares

Pedro Jares

Auto-generated profile, based on publicly available information

Pedro Jares

Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2008 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
GLG. Lenz
G. Lenz
GWG. Wright
G. Wright
SDS.S. Dave
S.S. Dave
WXW. Xiao
W. Xiao
JPJ. Powell
J. Powell
LSL.M. Staudt
L.M. Staudt
The addition of rituximab to combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), or R-CHOP, has significantly improved the survival of patients with diffuse large-B-cell lymphoma. Whether gene-expression signatures correlate with survival after treatment of diffuse large-B-cell lymphoma is unclear. We profiled gene expression in pretreatment biopsy specimens from 181 patients with diffuse large-B-cell lymphoma who received CHOP and 233 patients with this disease who received R-CHOP. A multivariate gene-expression–based survival-predictor model derived from a training group was tested in a validation group. A multivariate model created from three gene-expression signatures — termed “germinal-center B-cell,” “stromal-1,” and “stromal-2” — predicted survival both in patients who received CHOP and patients who received R-CHOP. The prognostically favorable stromal-1 signature reflected extracellular-matrix deposition and histiocytic infiltration. By contrast, the prognostically unfavorable stromal-2 signature reflected tumor blood-vessel density. Survival after treatment of diffuse large-B-cell lymphoma is influenced by differences in immune cells, fibrosis, and angiogenesis in the tumor microenvironment.

5 June 2011 in Nature
Verified
Journal Article
Open access
PDF file
XPXose S. Puente
Xose S. Puente
MPMagda Pinyol
Magda Pinyol
VQVíctor Quesada
Víctor Quesada
LCLaura Conde
Laura Conde
GOGonzalo R. Ordóñez
Gonzalo R. Ordóñez
ECElías Campo
Elías Campo
Analysis of the genomes of four patients with chronic lymphocytic leukaemia, and validation in more than 300 patients, has identified four genes — NOTCH1, MYD88, XPO1 and KLHL6 — that are recurrently mutated in the condition. Mutations in NOTCH1, MYD88 and XPO1 are thought to contribute to the clinical evolution of the disease. Evidence that NOTCH1 and MYD88 mutations are activating events highlights them as potential therapeutic targets. Chronic lymphocytic leukaemia (CLL), the most frequent leukaemia in adults in Western countries, is a heterogeneous disease with variable clinical presentation and evolution1,2. Two major molecular subtypes can be distinguished, characterized respectively by a high or low number of somatic hypermutations in the variable region of immunoglobulin genes3,4. The molecular changes leading to the pathogenesis of the disease are still poorly understood. Here we performed whole-genome sequencing of four cases of CLL and identified 46 somatic mutations that potentially affect gene function. Further analysis of these mutations in 363 patients with CLL identified four genes that are recurrently mutated: notch 1 (NOTCH1), exportin 1 (XPO1), myeloid differentiation primary response gene 88 (MYD88) and kelch-like 6 (KLHL6). Mutations in MYD88 and KLHL6 are predominant in cases of CLL with mutated immunoglobulin genes, whereas NOTCH1 and XPO1 mutations are mainly detected in patients with unmutated immunoglobulins. The patterns of somatic mutation, supported by functional and clinical analyses, strongly indicate that the recurrent NOTCH1, MYD88 and XPO1 mutations are oncogenic changes that contribute to the clinical evolution of the disease. To our knowledge, this is the first comprehensive analysis of CLL combining whole-genome sequencing with clinical characteristics and clinical outcomes. It highlights the usefulness of this approach for the identification of clinically relevant mutations in cancer.

11 December 2011 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
VQVíctor Quesada
Víctor Quesada
LCLaura Conde
Laura Conde
NVNeus Villamor
Neus Villamor
GOGonzalo R Ordóñez
Gonzalo R Ordóñez
PJPedro Jares
Pedro Jares
CLCarlos López-Otín
Carlos López-Otín

22 July 2015 in Nature
Verified
Journal Article
Closed access
PDF file
XPXose S. Puente
Xose S. Puente
SBSilvia Beà
Silvia Beà
RVRafael Valdés-Mas
Rafael Valdés-Mas
NVNeus Villamor
Neus Villamor
JGJesús Gutiérrez-Abril
Jesús Gutiérrez-Abril
ECElías Campo
Elías Campo

14 October 2012 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
MKMarta Kulis
Marta Kulis
SHSimon Heath
Simon Heath
MBMarina Bibikova
Marina Bibikova
AQAna C Queirós
Ana C Queirós
ANAlba Navarro
Alba Navarro
JMJosé I Martín-Subero
José I Martín-Subero

21 October 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SBSílvia Beà
Sílvia Beà
RVRafael Valdés-Mas
Rafael Valdés-Mas
ANAlba Navarro
Alba Navarro
ISItziar Salaverria
Itziar Salaverria
DMDavid Martín-Garcia
David Martín-Garcia
ECElías Campo
Elías Campo
Significance: This is a comprehensive whole-genome/whole-exome analysis of mantle cell lymphoma (MCL). We sequenced 29 MCL cases and validated the findings by target sequencing of 172 additional tumors. We identified recurrent mutations in genes regulating chromatin modification and genes such as NOTCH2 that have a major impact on clinical outcome. Additionally, we demonstrated the subclonal heterogeneity of the tumors already at diagnosis and the modulation of the mutational architecture in the progression of the disease. The identification of new molecular mechanisms may open perspectives for the management of MCL patients.